Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 May;105(5):1133-9.
doi: 10.1038/ajg.2010.9. Epub 2010 Feb 9.

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

Waqqas Afif  1 , Edward V Loftus Jr, William A Faubion, Sunanda V Kane, David H Bruining, Karen A Hanson, William J Sandborn
Affiliations
Comparative Study

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

Waqqas Afif et al. Am J Gastroenterol. 2010 May.

Abstract

Objectives: Human anti-chimeric antibodies (HACAs) and subtherapeutic infliximab concentrations are associated with decreased duration of response. We evaluated the clinical utility of measuring HACA and infliximab concentrations.

Methods: The medical records of patients with inflammatory bowel disease (IBD) who had HACA and infliximab concentrations measured were reviewed to determine whether the result affected clinical management.

Results: One hundred fifty-five patients had HACA and infliximab concentrations measured. The main indications for testing were loss of response to infliximab (49%), partial response after initiation of infliximab (22%), and possible autoimmune/delayed hypersensitivity reaction (10%). HACAs were identified in 35 patients (23%) and therapeutic infliximab concentrations in 51 patients (33%). Of 177 tests assessed, the results impacted treatment decisions in 73%. In HACA-positive patients, change to another anti-tumor necrosis factor (TNF) agent was associated with a complete or partial response in 92% of patients, whereas dose escalation had a response of 17%. In patients with subtherapeutic infliximab concentrations, dose escalation was associated with complete or partial clinical response in 86% of patients whereas changing to another anti-TNF agent had a response of 33%. Patients with clinical symptoms and therapeutic infliximab concentrations were continued at the same dose 76% of the time and had no evidence of active inflammation by endoscopic/radiographic assessment 62% of the time.

Conclusions: Measurement of HACA and infliximab concentration impacts management and is clinically useful. Increasing the infliximab dose in patients who have HACAs is ineffective, whereas in patients with subtherapeutic infliximab concentrations, this strategy may be a good alternative to changing to another anti-TNF agent.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

Guarantor of the article: Waqqas Afif, MD.

Potential competing interests: William Sandborn is a consultant to and has received research support from Centocor, Schering-Plough, Abbott Laboratories, and UCB Pharma. Edward Loft us has received research support from Schering-Plough and has participated in continuing medical education activities sponsored in part by Centocor. William Faubion is a consultant to and has received research support from Centocor and Abbot Laboratories. Dr Kane is a consultant to Abbott Laboratories.

Figures

Figure 1.
Figure 1.
Treatment algorithm in patients with clinical symptoms (infliximab and HACA concentrations). 1Patients should save endoscopic or radiologic imaging. 2This strategy may be preferable. HACA, human anti-chimeric antibody; TNF, tumor necrosis factor.
See this image and copyright information in PMC

Comment in

References

    1. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029–35. - PubMed
    1. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9. - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76. - PubMed
    1. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601–8. - PubMed
    1. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infliximab to clinical outcome aft er scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 2006;4:1248–54. - PubMed

Publication types

MeSH terms

LinkOut - more resources